Segments (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Information by Reportable Segment

Segment Adjusted EBITDA by reportable segment was as follows:

	Three Months Ended   September 30,				Nine Months Ended   September 30,
	2022		2021		2022		2021
Biopharmaceuticals	$	(12,417)	$	(12,661)	$	(35,286)	$	(34,055)
Exemplar	346		1,617		4,699		5,312
Segment Adjusted EBITDA for reportable segments	$	(12,071)	$	(11,044)	$	(30,587)	$	(28,743)

Revenues by reportable segment were as follows:

	Three Months Ended September 30, 2022
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	14,624	$	2,098	$	16,722
Intersegment revenues	—		—		—
Total segment revenues	$	14,624	$	2,098	$	16,722

	Three Months Ended September 30, 2021
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	129	$	3,204	$	3,333
Intersegment revenues	1,141		—		1,141
Total segment revenues	$	1,270	$	3,204	$	4,474

	Nine Months Ended September 30, 2022
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	14,778	$	10,368	$	25,146
Intersegment revenues	1,446		—		1,446
Total segment revenues	$	16,224	$	10,368	$	26,592

	Nine Months Ended September 30, 2021
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	723	$	9,860	$	10,583
Intersegment revenues	1,469		—		1,469
Total segment revenues	$	2,192	$	9,860	$	12,052

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:

	Three Months Ended   September 30,				Nine Months Ended   September 30,
	2022		2021		2022		2021
Segment Adjusted EBITDA for reportable segments	$	(12,071)	$	(11,044)	$	(30,587)	$	(28,743)
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	641		1,138		1,309		1,673
Add recognition of previously deferred revenue associated with upfront and milestone payments	14,561		1,163		16,007		1,849
Other expenses:
Interest expense	(2,036)		(4,765)		(6,137)		(13,902)
Depreciation and amortization	(1,717)		(2,029)		(5,470)		(6,174)
Gain on disposals of assets	—		(13)		—		(6)
Impairment losses	—		—		(1,120)		(543)
Stock-based compensation expense	(2,184)		(2,422)		(7,987)		(11,767)
Adjustment related to accrued bonuses paid in equity awards	—		—		1,698		—
Equity in net gain (loss) of affiliates	862		—		861		(3)
Other	—		(5)		(105)		(19)
Unallocated corporate costs	(5,744)		(7,166)		(24,718)		(24,835)
Eliminations	(6)		(1,237)		(1,549)		(1,812)
Consolidated net loss from continuing operations before income taxes	$	(7,694)	$	(26,380)	$	(57,798)	$	(84,282)

Reconciliation of Revenue from Segments to Consolidated

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:

	Three Months Ended   September 30,				Nine Months Ended   September 30,
	2022		2021		2022		2021
Total segment revenues from reportable segments	$	16,722	$	4,474	$	26,592	$	12,052
Elimination of intersegment revenues	—		(1,141)		(1,446)		(1,469)
Total consolidated revenues	$	16,722	$	3,333	$	25,146	$	10,583